The role of antithrombin III in critical patients in obstetrics

Minerva Anestesiologica

Volumn 68, Issue 5, 2002, Pages 449-453

  Mangione, S ^a,b   Giarratano, A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Antithombin III; Critical care; Critical illness; Obstetrics

Indexed keywords

ANTITHROMBIN III; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN C; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; SERINE PROTEINASE INHIBITOR;

ARTICLE; CESAREAN SECTION; DISEASE SEVERITY; FETUS MONITORING; HELLP SYNDROME; HUMAN; PREECLAMPSIA; PREGNANCY; ADOLESCENT; ADULT; CLINICAL TRIAL; FEMALE; INTENSIVE CARE; LABOR COMPLICATION;

ADOLESCENT; ADULT; ANTITHROMBIN III; BIOLOGICAL MARKERS; CRITICAL CARE; FEMALE; HUMANS; OBSTETRIC LABOR COMPLICATIONS; PRE-ECLAMPSIA; PREGNANCY; SERINE PROTEINASE INHIBITORS;

EID: 0036581845     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Redman CWG, Sacks GP Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
2. Brozovic M. Disseminated intravascular coagulation. In: Haemostasis and Thrombosis. New York: Churchill-Livingstone, 1987:535-41.
3. Esmon CT. The normal role of activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 2001;5:S7-12.
4. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Cytochines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 1995;80:519-26.
5. Giarratano A, Cuccio G, Mangione S. Effects of AT III treatment (high doses) in severe pre-eclampsia and HELLP syndrome with alterations of coagulation inhibitors and inflammatory markers: a preliminary report. Crit Care 2000;4:s17.
6. Giarratano A, Capogna G, Celleno D. A new approach in the treatment of severe preeclampsia and HELLP sindrome using high doses of Antithrombin III. Int Care Med 2000;26(3):S321-417.
7. Bick LR. Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thromb Hemost 1995;1:3-23.
8. Gilabert J, Fernandez JA, Espana F, Aznar J, Estelles A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res Suppl 1988;49(3):319-29.
9. Gore M, Eldon S, Trofatter KF, Soong SJ, Pizzo SV. Pregnancy-induced changes in the fibrinolytic balance: evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor. Am J Obstet Gynecol 1987;156(3):674-80.
10. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 by two distinct mechanism. Blood Cells Molec Dis 1995;21:156-67.
11. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res Suppl 1990;59(6):895-904.
12. Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. Thromb Haemost 2000;84(4):583-90.
13. Mangione S, Giarratano A, Leone I, Mangione D. Monitoraggio e trattamento delle coagulopatie in ostetricia ad alto rischio. Minerva Anestesiol 1996;62:623-6.
14. Okaijma K, Uchiba M. The anti-inflammatory properties of At III: new therapeutic implications in severe sepsis. Sem Thromb Hemostas 1998;24:3-18.
15. Paternoster DM, Stella A, Simioni P, Girolami A, Plebani M. Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. Eur J Obstet Gynecol Reprod Biol 1996;70(1):33-9.
16. Reister F, Heil W, Rath W. Coagulation disorders in Obstetrics. Biom Progr 1997;10:62-7.